ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1628

Decreased Levels Of Splicing Factor 2 / Alternative Splicing Factor (SF2/ASF) Correlate With Lower Transcript Levels Of The RasGRP1 Normal Isoform In Lupus T Cells

Takashi Kurita1, Shinsuke Yasuda1, Vaishali R. Moulton2, Michihito Kono1, Hideyuki Koide1, Kenji Oku1, Toshiyuki Bohgaki1, Olga Amengual1, Tetsuya Horita1, George C. Tsokos3 and Tatsuya Atsumi1, 1Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, 2Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: SLE and T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus-Human Etiology and Pathogenesis: Genetics and Genomics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Down-regulation of MAP kinase pathway has been recognized in T cells from patients with SLE that results in hypo-methylation of DNA. RasGRP1 is an intracellular signaling protein highly expressed in T cells and activates the Ras signaling pathway downstream of TCR engagement. RasGRP1 deficient mice develop late-onset lymphoproliferative autoimmune syndrome. Previously we reported that defective (alternatively spliced) RasGRP1 transcripts correlate with lower levels of RasGRP1 protein in SLE T cells (Yasuda S et.al. J Immunol 2007). Splicing factor 2 / Alternative Splicing factor (SF2/ASF) is a member of the serine arginine family of splicing proteins that binds pre-mRNA to regulate alternative splicing. For instance, SF2/ASF binds to the 3’UTR of CD3 zeta and enables normal splicing of this signaling protein. (Moulton V et.al. J Biol Chem. 2010). The purpose of this study is to determine the relationship between aberrant splicing of RasGRP1 and SF2/ASF expression in SLE T cells.

Methods: Forty-five SLE patients and eighteen healthy subjects were included in this study. T cells were collected from peripheral blood of each subject and RNA was isolated. Expression levels of SF2/ASF, normally spliced RasGRP1 and DNMT1 transcripts were assessed by real time quantitative PCR. RNA electrophoretic mobility shift assays (EMSA) and immunoprecipitations (IP) were performed to confirm the direct binding of SF2 to RasGRP1 pre-mRNA. RasGRP1 exon11 RNA oligonucleotides end-labeled with biotin and recombinant SF2/ASF phosphate mimic were used in these experiments.

Results: Expression levels of SF2/ASF transcripts were significantly lower in SLE patients compared with healthy subjects (p=0.001, t-test). In patients with SLE, expression levels of SF2/ASF correlated with those of normally spliced RasGRP1 and DNMT1 (r=0.517, p=0.023 [RasGRP1]; r=0.557, p=0.013 [DNMT1], Figure). EMSA and IP studies suggested that SF2/ASF binds directly to RasGRP1 exon 11 RNA.

Conclusion: SF2/ASF binds to RasGRP1 mRNA and controls its expression. Low SF2/ASF levels in SLE T cells correlate with the expression levels of RasGRP1 and DNMT1. We propose that SF2/ASF regulates the alternative splicing of important genes in SLE T cells including RasGRP1 and CD3 zeta.


Disclosure:

T. Kurita,
None;

S. Yasuda,
None;

V. R. Moulton,
None;

M. Kono,
None;

H. Koide,
None;

K. Oku,
None;

T. Bohgaki,
None;

O. Amengual,
None;

T. Horita,
None;

G. C. Tsokos,
None;

T. Atsumi,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decreased-levels-of-splicing-factor-2-alternative-splicing-factor-sf2asf-correlate-with-lower-transcript-levels-of-the-rasgrp1-normal-isoform-in-lupus-t-cells/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology